Safety and efficacy of ripasudil eye drops in preterm infants with retinopathy of prematurity: phase 1/2, open label, single-arm trial
Japanese Journal of Ophthalmology · 2024
DOI: 10.1007/s10384-024-01100-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Japanese Journal of Ophthalmology, 2024. Verfasst von Mitsuru Arima und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka City, Fukuoka, 812-8582, Jap…. Hauptthemen laut MEDLINE: Retinopathy of Prematurity, Ophthalmic Solutions, Isoquinolines, Gestational Age. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: the Japan Agency for Medical Research and Development.
Themen: Neonatologie
Abstract (Originalsprache)
PURPOSE: To assess the safety and efficacy of ripasudil for retinopathy of prematurity (ROP). STUDY DESIGN: Phase 1/2, multicenter, open-label, single-arm, 12-week clinical trial. METHODS: Infants born with gestational age (GA) of ≤ 32 weeks or weight of ≤ 1500 g with zone I or II, ≥ stage 1, ROP in both eyes were enrolled. Ripasudil eye drops were administered to patients in both eyes. Phase 1 was a dose-escalation study (once daily for 1 week, then twice daily for 2 weeks); an additional dosing up to 9 weeks was allowed if no safety issues occurred. In phase 2, ripasudil was administered twice daily for up to 12 weeks. Adverse events were assessed. The proportion of patients with type 1 ROP progression, number of days for type 1 ROP progression, and progression to the most advanced ROP stage were estimated. RESULTS: Twenty-four infants were enrolled (phase 1, n = 3; phase 2, n = 21). Nineteen and four patients experienced systemic and ocular adverse events, respectively. Efficacy endpoints were not different between the ripasudil and historical control groups. However, in the GA ≤ 27 weeks subgroup, fewer patients progressed to type 1 ROP in the ripasudil than in the historical control group (P = 0.09). In the GA ≤ 27 weeks subgroups, the 25th percentile for the number of days for type 1 ROP progression was 22 days in the historical control group and 44 days in the ripasudil group. CONCLUSION: Ripasudil was safe and inhibited/delayed type 1 ROP progression, especially in infants with short GA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka City, Fukuoka, 812-8582, Japan. marima4802@gmail.com.
- Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan. marima4802@gmail.com.
- Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
- Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka City, Fukuoka, 812-8582, Japan.
- Department of Ophthalmology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Förderung
- the Japan Agency for Medical Research and Development
Zitieren
APA
Arima, M., Inoue, H., Misumi, A., Tsukamoto, S., Matsushita, I., Araki, S., Ohta, M., Takahashi, K., Imazato, M., Goto, T., Aoki, Y., Tagawa, K., Hirose, M., Fujita, Y., Yoshida, N., Nakao, S., Kondo, H., Kusuhara, K., Kimura, K., …, & Sonoda, K. H. (2024). Safety and efficacy of ripasudil eye drops in preterm infants with retinopathy of prematurity: phase 1/2, open label, single-arm trial. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-024-01100-3
Vancouver
Arima M, Inoue H, Misumi A, Tsukamoto S, Matsushita I, Araki S, et al. Safety and efficacy of ripasudil eye drops in preterm infants with retinopathy of prematurity: phase 1/2, open label, single-arm trial. Japanese Journal of Ophthalmology. 2024. doi:10.1007/s10384-024-01100-3
BibTeX
@article{Arima2024,
author = {Arima, Mitsuru and Inoue, Hirosuke and Misumi, Akiko and Tsukamoto, Shoko and Matsushita, Itsuka and Araki, Shunsuke and Ohta, Manami and Takahashi, Kazumasa and Imazato, Miyuki and Goto, Tomoko and Aoki, Yoshinori and Tagawa, Koshiro and Hirose, Masayuki and Fujita, Yuito and Yoshida, Noriko and Nakao, Shintaro and Kondo, Hiroyuki and Kusuhara, Koichi and Kimura, Kazuhiro and Hasegawa, Shunji and Ikeda, Yasuhiro and Kodama, Yuki and Moritake, Hiroshi and Ochiai, Masayuki and Ohga, Shouichi and Kishimoto, Junji and Todaka, Koji and Ieiri, Ichiro and Sonoda, Koh-Hei},
title = {Safety and efficacy of ripasudil eye drops in preterm infants with retinopathy of prematurity: phase 1/2, open label, single-arm trial},
journal = {Japanese Journal of Ophthalmology},
year = {2024},
doi = {10.1007/s10384-024-01100-3}
}
EUVIMED